Jenni Bell MD

Adv HF & Transplant Cardiologist 🫀| AHFT Program Director | Asst Prof @UConn SOM 🩺 | Wife | Mom | Formula 1 fan 🏎 | opinions=own

[Robert Mentz, MD @robmentz]

New HFpEF consensus pathway lays out clear approach:
💠SGLT2i + (ns)MRA, unless contraindicated
💠+GLP1, if obese
💠Consider ARNI
💠AVOID BB as able
CKM GL give framework in context of comorbidities.
🚨Need to make sure we don't delay effective therapies down the decision tree!🚨

[Gregg Fonarow MD @gcfmd]

New onset HFrEF

ARNI+BB+MRA+SGLT2i ➡️

75% ⬇️ all-cause ☠️ (26% ARR, NNT=4, 24 months)

85% ⬇️ HF 🏨 (33% ARR, NNT=3)

Extend median survival 7-11 years

Cost $125/month (cash pay, cost plus mail order)

Worth it?

[Michael Weintraub, MD @MWeintraubMD]

Kidney transplant recipients receiving GLP-1 RA had a 49% lower incidence of death-censored graft loss and 31% lower mortality than those not receiving GLP-1 RA 🤯

Proud to be a co-author on this real-world retrospective cohort study of 18,106 kidney transplant recipients with diabetes published today in Lancet Diabetes and Endocrinology🙂

Article: https://t.co/gNRoxCW57v

Accompanying commentary: https://t.co/I1MvUKcLI4

[Jenni Bell MD @jennibellMD]

@Dr_mac2 I often get patients late in their heart failure and I’m reviewing their medical care for the past decade or more completely horrified… it’s a scary world out there

[Quinn Capers, IV @DrQuinnCapers4]

This morning @ACCinTouch launched its 4th IM Mentoring Program (Hispanic Cohort) to mentor young Drs who aspire to be cardiologists. 45 residents heard from prominent Hispanic heart docs. Our goal: to reducehealthcare disparities by increasing diversity in medicine.

[Women in Heart Transplantation and MCS @Womenintxp_mcs]

Join us in Prague for town hall discussion!
📅Apr 13, 2024
⏲️5:30 PM CET
Open to everyone attending #ISHLT2024
@shelleyhallmd @dranulala @NutritionHF @IRajapreyar @DhariniRamu @rcogswell_umn @docbhardwaj @AditiNayakMD @JeffTeuteberg @RyanTedfordMD @PalakShahMD @manreetkanwar

[ChonyAlbert MD @ChonyAlbertMD]

@manreetkanwar presents powerful data on improving both quality and duration of life in LVAD patients. Optimize hemodynamics. GDMT for remission/recovery. Monitor drive line like it’s a “third limb.” Silver, chlorhexadine, and stringent diabetes control. #ishlt2024 @ISHLT

[Houston Shock Symposium @HoustonShockHSS]

#HSS24
Behind the scene! 🎬 Join us starting TOMORROW (3/22-3/24).
✅Inaugural SHOCK Jeopardy 🥇
✅Hand-on Skills Lab 💉
✅Publications Lounge 📚
✅Nursing & APP Summit 🏥
✅Industry-sponsored sessions 💥
✅Lectures and 🔥 debates
Free registration on-site! @JumeanMarwan

[Houston Shock Symposium @HoustonShockHSS]

Join us at the Houston Shock Symposium where Dr. @AlexandraLansky will delve into a highly relevant subject concerning risk models in cardiogenic shock, exploring their effectiveness and applicability.

#HSS24 #Cardiotwitter #ACCFIT

[JACC Journals @JACCJournals]

New #JACCHF state-of-the-art review provides a comprehensive approach to the use of invasive hemodynamic assessments in patients supported with LVADs. https://t.co/c7MFSK41iU

#LVAD #HeartFailure @FilioBillia

[Khristian Burke @burke_khristian]

🚨Calling #ACCMedStudent & #ACCMedResident members 🚨

So excited to bring you our first webinar of 2024 - Join us for a great discussion on Hemodynamics! A special thank you to Dr. Anavekar for dedicating your time to mentor our community! #MedEd #CardioTwitter 🫀🩺

[Anju Bhardwaj MD FACC @docbhardwaj]

🔥🔥🔥Value of Invasive Hemodynamics assessment in #LVAD patients: State of Art Review in @JACCJournals #JACCHF by team @FilioBillia

🏷️ ⬆️ burden of HRAEs with #LVAD
🏷️ IHA allow speed optimization & symptom evaluation with tailored Mx
🏷️Echo doesn’t reflect unloading

[Jenni Bell MD @jennibellMD]

@DrNasrien How I see you 🥹

[Jenni Bell MD @jennibellMD]

Keeping patients alive with good QOL on GDMT... only for them to be diagnosed with metastatic CA. It's devastating.

[Jenni Bell MD @jennibellMD]

@KadijahPorterMD As a latina dr and one who participates in interviewing candidates, I am acutely aware of how black/brown and female candidates are perceived differently and have various hoops to jump through their counterparts do not.

[Jenni Bell MD @jennibellMD]

Performative activism

[Kadijah F Porter MD @KadijahPorterMD]

Kept seeing the Cardiology fellowship match composites from ‘elite institutions’ and you know what sticks out the most to me? The actual ABSENCE of diversity. Which made me peruse a few websites and I was not surprised to discover the lack of diversity throughout the department🙃

[Jenni Bell MD @jennibellMD]

@KadijahPorterMD Omg kadijah I meant the programs! There is constant talk from CV programs to increase diversity but do the bare minimum to actually accomplish this. I am so sorry I wasn't clear!

[Jenni Bell MD @jennibellMD]

😬 dismal.

[Eiran Gorodeski, MD, MPH @EiranGorodeski]

Match results for 2024, reported today, suggest again that interest in AHFTC is low. Of n=73 programs participating in the match n=30 were filled and n=43 went unfilled (59% of programs unmatched). Of n=129 available positions, n=73 filled and n=56 (43%) unfilled. #NRMP

[Abdulla A. Damluji, MD, PhD @DrDamluji]

Semaglutide and Cardiovascular Outcomes
in Obesity without Diabetes: @NEJM

The select trial: #AHA23

🥸Wow! @AHA_Research

😱Now on the stage in main event

😱Let's get the highlights

👇👇👇

[C. Michael Gibson MD @CMichaelGibson]

ARIES-HM3 Trial: In patients with HF receiving HM3 LVAD, VKA alone without aspirin results in no change in thrombotic outcomes, significantly less bleeding and less hospitalizations.

Download slides for the ARIES-HM3 trial on excluding aspirin in LVAD HM3 presented at #AHA23 Link here: https://t.co/1VAuUj8Wnz